MAPT and early-onset autosomal dominant Alzheimer disease: Secondary outcomes include inflammatory biomarkers, Mini-Mental State Examination, CDR, ADAS-cog, Alzheimer’s Disease Cooperative Study Activities of Daily Living (ADCS ADL) scale, Free and Cued Selective Reminding Test, and CSF amyloid and phospho-tau measures.